Neoadjuvant Dual vs Single Checkpoint Inhibitors in High-Ris

1. The pathological response rate had an OR of 3.16 when comparing neoadjuvant dual vs single checkpoint inhibitors. 2. The grade 3-4 immune-related adverse event rate had an OR 3.75 when comparing neoadjuvant dual vs single checkpoint inhibitors. Evidence Rating Level: 1 (Excellent) Study Rundown: Adjuvant therapy in resected advanced melanoma with immune checkpoint inhibitors

Related Keywords

, Rating Level , Early Stage Melanoma , Melanoma , Neoadjuvant Immunotherapy , Chronic Disease , Oncology ,